NPS Pharmaceuticals to Present at Upcoming Healthcare Conferences

  NPS Pharmaceuticals to Present at Upcoming Healthcare Conferences

Lazard Capital Markets 9th Annual Healthcare Conference New York 2012
Jefferies Global Healthcare Conference London 2012

Business Wire

BEDMINSTER, N.J. -- November 07, 2012

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is scheduled to present at the Lazard
Capital Markets 9^th Annual Healthcare Conference in New York on Wednesday,
November 14, 2012 at 9:30 a.m. ET and the Jefferies 2012 Global Healthcare
Conference in London Thursday, November 15, 2012 at 10:00 a.m. WET.
Presentations will be available as live webcasts with replays available
approximately three hours after the presentations have concluded. Interested
parties may access the webcast from the investors’ calendar of events page on
the NPS website at

About NPS Pharmaceuticals

NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan
products to patients with rare disorders and few, if any, therapeutic options.
NPS is advancing two late-stage registration programs. A New Drug Application
is undergoing FDA review for Gattex® (teduglutide) as a treatment for adults
with short bowel syndrome (SBS) and a Biologic License Application is being
prepared for Natpara® (rhPTH[1-84]) in adult hypoparathyroidism. NPS' earlier
stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with
potential application in rare disorders involving increased calcium receptor
activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH).
NPS complements its proprietary programs with a royalty-based portfolio of
products and product candidates that includes agreements with Amgen,
GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin, and Nycomed, a
Takeda company.


NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335
Press spacebar to pause and continue. Press esc to stop.